Hypoactive Sexual Desire Disorder

Addyi met endpoints for sexually satisfying events, distress, and desire. Addyi may also produce a satiety-like effect via dopamine pathways, with some women losing up to 5% of body weight. Addyi required six years to gain FDA approval compared to six months for Viagra, illustrating a disparity in regulatory attention to women's sexual medicine. Vyleesi and Addyi differ in use, and treatment should be one or the other rather than both together. Less than 30% of OB-GYNs are trained in sexual health, meaning most patients do not receive a full HSDD evaluation unless they find a specialist. Addyi and Vyleesi should not be used together. Low libido in women has multiple interacting causes rather than a single cause. Addyi and Vyleesi are the only two FDA-approved non-hormonal treatments for low sexual desire in women; both work by modulating neurotransmitter signaling rather than acting mechanically like Viagra. MRI research found that women with HSDD show reduced activation in desire and reward brain regions and increased activation in inhibitory regions compared to women without the disorder. Relationship quality, partner attraction, neurochemistry, hormones, lifestyle demands, illn…